Therapeutic Target Details
| Target ID: | T26 |
| Target Name: | Thyroid hormone receptor beta |
| Synonyms: | c-erbA-2; c-erbA-beta; ERBA2; NR1A2; Nuclear receptor subfamily 1 group A member 2; THR1; Thyroid receptor β; THRB |
| GENE: | THRB |
| Action: | agonist |
| Class: | Nuclear hormone receptor |
| UniProtKB ID: | P10828 |
| Entry Name: | THB_HUMAN |
| Related Drugs: | Levothyroxine; VK-2809; MGL-3196; Resmetirom |
| Mechanism: | Thyroid hormones are involved in the regulation of hepatic triglyceride and cholesterol metabolism. Thyroid hormones reduce serum cholesterol by affecting cholesterol synthesis, LDL clearance, and reverse cholesterol transport. In this respect, thyroid hormone receptor-β (THR-β), which is mainly expressed in the liver, could be a target for NAFLD treatment. |
| Reference (PMIDs): | 31389309 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D203 | Levothyroxine | Chemical drug | DB00451 | THRA agonist; THRB agonist | Anti-fibrosis | Under clinical trials | Details |
| D461 | ALG-055009 | Chemical drug | -- | Thyroid hormone receptor beta agonist | -- | Under clinical trials | Details |
| D581 | sobetirome | Chemical drug | -- | Thyroid hormone receptor beta agonists | Enhance lipid metabolism | Under investigation | Details |
| Candidate ID | Source ID | Source Type | Compound Type | Candidate Name | Inclusion Criteria | |
|---|---|---|---|---|---|---|
| R0102 | DB00279 | approved; vet_approved | small molecule | Liothyronine | Target associated | Details |
| R0174 | DB00509 | approved; investigational | small molecule | Dextrothyroxine | Target associated | Details |
| R0534 | DB01583 | approved | small molecule | Liotrix | Target associated | Details |
| R0558 | DB02106 | experimental | small molecule | [3,5-Dibromo-4-(4-Hydroxy-3-Phenethylcarbamoyl-Phenoxy)-Phenyl]-Acetic Acid | Target associated | Details |
| R0577 | DB03176 | experimental | small molecule | KB-141 | Target associated | Details |
| R0578 | DB03181 | experimental | small molecule | 2-[4-(4-Hydroxy-3-Isopropyl-Phenoxy)-3,5-Dimethyl-Phenyl]-2h-[1,2,4]Triazine-3,5-Dione | Target associated | Details |
| R0589 | DB03604 | investigational | small molecule | Tiratricol | Target associated | Details |
| R0593 | DB03788 | experimental | small molecule | GC-24 | Target associated | Details |
| R0681 | DB05035 | investigational | small molecule | Eprotirome | Target associated | Details |
| R0729 | DB05192 | investigational | small molecule | MB07811 | Target associated | Details |
| Compound ID | Source ID | Source Type | Compound Name | Molecular Weight | Molecular Formula | Molecular Species | |
|---|---|---|---|---|---|---|---|
| B000007 | CHEMBL10041 | Small molecule | AFIMOXIFENE | 387.52 | C26H29NO2 | BASE | Details |
| B000036 | CHEMBL101263 | Small molecule | 4-NITROBENZOIC ACID | 167.12 | C7H5NO4 | ACID | Details |
| B000046 | CHEMBL101519 | Small molecule | -- | 429.52 | C27H27NO4 | BASE | Details |
| B000076 | CHEMBL102426 | Small molecule | -- | 356.51 | C22H32N2O2 | BASE | Details |
| B000083 | CHEMBL103 | Small molecule | PROGESTERONE | 314.47 | C21H30O2 | NEUTRAL | Details |
| B000085 | CHEMBL103102 | Small molecule | -- | 127.19 | C6H13N3 | BASE | Details |
| B000100 | CHEMBL103955 | Small molecule | CHAETOMELLIC ACID A | 326.48 | C19H34O4 | ACID | Details |
| B000104 | CHEMBL1042 | Small molecule | CHOLECALCIFEROL | 384.65 | C27H44O | NEUTRAL | Details |
| B000120 | CHEMBL1046 | Small molecule | AMINOCAPROIC ACID | 131.18 | C6H13NO2 | ZWITTERION | Details |
| B000139 | CHEMBL105310 | Small molecule | 2',4'-DIHYDROXYCHALCONE | 240.26 | C15H12O3 | NEUTRAL | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A01793 | 34615727 | Gut | Novel therapeutic targets for cholestatic and fatty liver disease. | Details |
| A02057 | 34517466 | Zhonghua Gan Zang Bing Za Zhi | [New development for targeted therapy of non-alcoholic fatty liver disease with thyroid hormone receptor beta]. | Details |
| A26543 | 20236931 | J Biol Chem | Thyroid hormone regulates hepatic expression of fibroblast growth factor 21 in a PPARalpha-dependent manner. | Details |
| A42819 | 33353459 | Thyroid | Increased Hepatic Fat Content in Patients with Resistance to Thyroid Hormone Beta. | Details |
| A46465 | 18434432 | FASEB J | Thyroid hormone (T3) and TRbeta agonist GC-1 inhibit/reverse nonalcoholic fatty liver in rats. | Details |
| A51306 | 35735253 | Hepatol Commun | Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosis. | Details |